Compare AstraZeneca plc (AZN) vs iShares MSCI India ETF (INDA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs iShares MSCI India ETF — how do they compare? AstraZeneca plc trades at $158.4 (market cap $248.14B), while iShares MSCI India ETF trades at $49.96. The key difference: AstraZeneca plc pays a 2.01% dividend while iShares MSCI India ETF pays none, and iShares MSCI India ETF is trading nearer its 52-week high, AstraZeneca plc nearer its low. Which is the better fit depends on your goals.
| AZN | INDA | |
|---|---|---|
Market Cap | $248.14B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $209.48 | $55.29 |
52-Week Low | $147.06 | $45.42 |
Enterprise Value | $275.41B | — |
Dividend Yield | 2.01% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $158.48, down 2.12% amid bearish technical signals and merger speculation. The stock shows strong fundamentals with revenue growth from $54.1B in 2024 to $58.7B in 2025 and net income reaching $10.2B. Recent earnings beats and a 47.5% analyst buy rating contrast with technical indicators showing oversold conditions near key support at $155.
Investment outlook remains positive based on earnings momentum and valuation metrics (P/E 23.76), though risks include potential merger integration challenges and ongoing legal investigations. The company's robust cash flow generation and dividend payments provide shareholder value support despite near-term volatility.
INDA trades at $49.95, down 0.38% on the day, with technical indicators showing a bullish trend supported by moving averages but neutral oscillators. The ETF reflects exposure to India's economy, which grew 7.8% in Q1 2026 (CNBC, 2026-06-05), though financial ratios are unavailable. Recent news highlights sector-specific challenges, including IT weakness and pharmaceutical export hurdles.
The outlook for INDA is mixed, with India's robust economic growth offering long-term potential, but near-term risks from foreign outflows, geopolitical tensions, and sectoral headwinds may pressure performance. Investors should weigh macroeconomic resilience against volatility in key industries like technology and pharma.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About iShares MSCI India ETF
INDA tracks the MSCI India Index, providing broad exposure to large and mid-cap companies in the Indian stock market. It is structurally dominated by the financials, information technology, and energy sectors, serving as a core instrument for investors seeking a single-country view of India's long-term economic growth.
Read more on INDA →
